Carl June
Patrimonio netto: 160 783 $ in data 30/06/2026
Patrimonio netto: 160 783 $ in data 30/06/2026
Carl H.
June is the founder of Tmunity Therapeutics, Inc. Dr. June is Director at the American Association for Cancer Research since 2018.
Dr. June is Director at The Parker Institute For Cancer Immunotherapy.
Dr. June is Independent Director at AC Immune SA since 2020.
Dr. June is Senior Advisor at Arsenal Capital Management LP.
Formerly, Dr. June was Advisor at Signature Capital LLC and Advisor at GBP Capital.
Dr. June earned a doctorate from Baylor College of Medicine in 1979 and an undergraduate degree from the United States Naval Academy in 1975.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
AC IMMUNE SA 0,07% | 11/06/2026 | 67.556 ( 0,07% ) | 160 783 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| AC IMMUNE SA | Direttore/Membro del Consiglio | 20/11/2020 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Fondatore | - |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services Engages in research, education, communication and collaboration to prevent and cure cancer | Direttore/Membro del Consiglio | 01/01/2018 |
The Parker Institute For Cancer Immunotherapy
The Parker Institute For Cancer Immunotherapy Miscellaneous Commercial ServicesCommercial Services Operates cancer research | Direttore/Membro del Consiglio | - |
Arsenal Capital Management LP
Arsenal Capital Management LP Investment ManagersFinance Arsenal Capital invests in middle market companies located in the United States. The firm focuses on healthcare and industrial sectors. It participates in buyouts, add-on acquisitions and growth stage capital transactions. | Consulente / Consigliere | - |
| Società | Posizione | Fine |
|---|---|---|
Signature Capital LLC
Signature Capital LLC Investment ManagersFinance Signature invests in early-stage growth technology companies in the following areas: electronic equipment/devices, application-specific semiconductor products, telecommunications, medical/biotechnology (healthcare products or therapies), Internet businesses and technology based service companies. They look for companies that have a proprietary position in timely new products or services and serve a large, established market that will allow rapid scalability of revenue to over $100 million per year. The company must strong, visionary managers and be in a field with good valuations in the securities markets | Corporate Officer/Principal | - |
GBP Capital
GBP Capital Investment ManagersFinance GBP Capital provides venture funding and assistance to early and mid-stage life science companies. They target companies with unique approaches to diagnostics, therapeutics and medical devices. GBP Capital focuses on investing in companies with technologies that leverage and build upon medical breakthroughs, as well as other major developments taking place within the life-sciences industry. | Investitore di Private Equity | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
AC Immune SA
AC Immune SA Pharmaceuticals: MajorHealth Technology Manufactures precision medicines for neurodegenerative diseases | Health Technology |
Arsenal Capital Management LP
Arsenal Capital Management LP Investment ManagersFinance Arsenal Capital invests in middle market companies located in the United States. The firm focuses on healthcare and industrial sectors. It participates in buyouts, add-on acquisitions and growth stage capital transactions. | Finance |
Signature Capital LLC
Signature Capital LLC Investment ManagersFinance Signature invests in early-stage growth technology companies in the following areas: electronic equipment/devices, application-specific semiconductor products, telecommunications, medical/biotechnology (healthcare products or therapies), Internet businesses and technology based service companies. They look for companies that have a proprietary position in timely new products or services and serve a large, established market that will allow rapid scalability of revenue to over $100 million per year. The company must strong, visionary managers and be in a field with good valuations in the securities markets | Finance |
United States Naval Academy
United States Naval Academy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Baylor College of Medicine
Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services Engages in research, education, communication and collaboration to prevent and cure cancer | Commercial Services |
GBP Capital
GBP Capital Investment ManagersFinance GBP Capital provides venture funding and assistance to early and mid-stage life science companies. They target companies with unique approaches to diagnostics, therapeutics and medical devices. GBP Capital focuses on investing in companies with technologies that leverage and build upon medical breakthroughs, as well as other major developments taking place within the life-sciences industry. | Finance |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
The Parker Institute For Cancer Immunotherapy
The Parker Institute For Cancer Immunotherapy Miscellaneous Commercial ServicesCommercial Services Operates cancer research | Commercial Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale